Skip to Content

Clinical Trials Detail

SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.

Objective
This is a clinical trial of tamoxifen and an aromatase inhibitor that will be administered by mouth, which is standard of care and docetaxel, cyclophosphamide, paclitaxel, doxorubicin, and/or 5-FU selected regimens that will be administered by IV, and is standard of care.
IRB Protocol Number
11-0709
Principal Investigator(s)
ANTHONY ELIAS

Cancer Trials

  • Breast Cancer
Sponsor(s)
SWOG
Contact
KYRA ANDERSON at
or KYRA.ANDERSON@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last up to 10 years. A follow up period will consist of clinic visits for up to 15 years. // Eligibility criteria include but are not limited to 18 years or older with breast cancer.

Location

  • Alamosa
  • Dept Of Veterans Affairs Medical Center
  • Montrose Memorial Hospital
  • Shaw Regional Cancer Center (Vail)
  • ST. MARYS HOSPITAL - G.J.
  • Valley View Hospital